Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCHERING-PLOUGH MOVES RICHARD KOGAN, 44, TO PRESIDENT AND COO

Executive Summary

SCHERING-PLOUGH MOVES RICHARD KOGAN, 44, TO PRESIDENT AND COO, effective Jan. 1, the company announced in a Nov. 11 release. Kogan takes over the president spot from Chairman and CEO Robert Luciano and assumes the chief operating officer spot, vacated in February 1981 with Luciano's promotion to CEO. Currently exec VP-pharmaceutical operations in charge of Schering's worldwide pharmaceutical operations and R&D and vision care business, Kogan will take on the additional responsibility for consumer operations and human resources, Schering reported. Kogan already sits on the Schering board. Kogan came on board as exec VP-pharmaceuticals when he joined Schering in April 1982 from Ciba-Geigy. He had served as president of the Swiss firm's U.S. pharmaceutical div. from 1980 to 1982. While moving through the ranks at Ciba-Geigy, Kogan had worked under Luciano, who from 1974-1977 had been president of Ciba-Geigy's U.S. pharmaceutical business. Kogan had joined Ciba Pharmaceuticals as manager of long-range planning in 1968 after entering the pharmaceutical industry in 1966 with Warner-Lambert. Assuming direct control of Schering's worldwide pharmaceutical operations and Wesley Jessen as group VP-pharmaceutical operations will be current Schering U.S. President Donald Conklin, 49. In addition to pharmaceuticals and vision care, Conklin will also have the company's planning and policy development, business development and human resources functions reporting to him. A 26-year veteran at Schering-Plough, Conklin held "various marketing positions" before he became director of marketing in 1967, Schering said. He was appointed VP-marketing for Schering Internatl. in 1977 and, subsequently, senior VP-internatl. headquarters in 1983. Conklin assumed his present position as president of Schering U.S. on Jan. 1 of this year. He is a graduate of Williams College and received an MBA from Rutgers University Graduate School of Business. Conklin will continue to report to Kogan in his new position, as president and COO, as will Pharmaceutical Research Div. President Alexander Lane, MD. Also reporting to Kogan will be Exec VP-Consumer Operations Lee Jenkins and Exec VP-Human Resources Stephen Byrd. Kogan, newly-promoted Exec VP-Finance Harold Hiser, and Exec VP-Administration Hugh D'Andreade will report to Luciano. In a separate Nov. 11 release, Schering announced that it had sent a letter to shareholders outlining a new rights dividend plan -- or "poison pill." Schering said that the dividend distribution purchase rights "should deter any attempt to acquire the company in a manner, or on terms, not approved by the board and should deter any attempt by a 20% shareholder to take advantage of the company through self-dealing transactions." The rights will be distributed on Nov. 22, 1985 to shareholders of record on that date and can be triggered by the purchase of 20% or more shares or a hostile tender offer for at least 30% of Schering outstanding stock.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS009280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel